XNAS
TARA
Market cap153mUSD
Oct 08, Last price
2.65USD
1D
2.32%
1Q
-38.66%
Jan 2017
-96.51%
IPO
-99.34%
Name
Protara Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
42.72%
Rev. gr., 5y
%
Revenues
0
Net income
-57m
L+28.80%
CFO
-56m
L+57.41%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Key people
Jesse Shefferman
President, Chief Executive Officer, Director · since 2020
Steven K. Burke
Senior Vice President, Chief Medical Officer · since 2006
E. Scott Toner
Senior Vice President - Marketing · since 2015
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer · since 2020
Daniel P. Gottlieb
Vice President - Corporate Development · since 2013
Matthew Paul Kowalsky
Vice President, Legal and Secretary · since 2016
Bradley J. Hartman
Vice President, People · since 2018
George A. Eldridge
Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary, · since 2013
Chairman of the Board · since 2020
Independent Director · since 2007
Independent Director · since 2014
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
200 West Street
Waltham, MA 02451
US
Waltham, MA 02451
US
Previous name
PROTEON THERAPEUTICS, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||